23 September 2025   Vienna-based Heartbeat.bio , developer of breakthrough therapies for cardiac disorders through its proprietary human-based in vitro cardioid drug discovery platform, announces  it has entered into a research collaboration with Boehringer Ingelheim to develop gene therapy-based treatments for genetic cardiomyopathies.   Genetic cardiac pathologies such as hypertrophic, dilated, arrhythmogenic right ventricular and restrictive cardiomyopathy, are typically c

31 January 2026   Mahzi Therapeutics-sponsored Phase 1/2 study  to assess safety and efficacy of MZ-1866 gene therapy for children and adults with Pitt Hopkins syndrome is about to start. The trial was announced  by Mahzi in 2025, highlighting the sponsor's collaboration with the Pitt Hopkins Research Foundation and the Muotri Lab at UC San Diego in developing this long awaited treatment.   Pitt-Hopkins syndrome (PHS) is a rare genetic disorder caused by mutations in the tran